Role of SHP2/PTPN11 in the occurrence and prognosis of cancer: A systematic review and meta-analysis

作者全名："Li, Shu; Wang, Xiaotong; Li, Qiuhong; Li, Chunli"

作者地址："[Li, Shu; Li, Qiuhong; Li, Chunli] Chongqing Med Univ, Dept Clin Lab, Women & Childrens Hosp, Chongqing 401174, Peoples R China; [Li, Shu; Li, Qiuhong; Li, Chunli] Chongqing Hlth Ctr Women & Children, Dept Clin Lab, Chongqing 401174, Peoples R China; [Wang, Xiaotong] Chongqing Med Univ, Dept Obstet & Gynecol, Women & Childrens Hosp, Chongqing 401174, Peoples R China; [Wang, Xiaotong] Chongqing Hlth Ctr Women & Children, Dept Obstet & Gynecol, Chongqing 401174, Peoples R China; [Li, Chunli] Chongqing Hlth Ctr Women & Children, Dept Clin Lab, 120 Longshan Rd, Chongqing 401174, Peoples R China"

通信作者："Li, CL (通讯作者)，Chongqing Hlth Ctr Women & Children, Dept Clin Lab, 120 Longshan Rd, Chongqing 401174, Peoples R China."

来源：ONCOLOGY LETTERS

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000910708200001

JCR分区：Q3

影响因子：2.5

年份：2023

卷号：25

期号：1

开始页：　

结束页：　

文献类型：Review

关键词：PTP non-receptor type 11; Src homology-2 domain-containing protein tyrosine phosphatase; meta-analysis; prognosis

摘要："Src homology-2 domain-containing protein tyrosine phosphatase (SHP2)/PTP non-receptor type 11 (PTPN11) have been reported to be expressed in a variety of solid tumors, though its role in tumors remains controversial. The aim of the present study was to explore the role of SHP2/PTPN11 in the occurrence and prognosis of cancer. Literature on the relationship between SHP2/PTPN11 expression and tumor was searched in PubMed, China National Knowledge Infrastructure and Cochrane Library electronic database, following which the Stata 12.0 software was used for meta-analysis. A total of 23 articles were included in the present statistical analysis. Higher expression levels of SHP2/PTPN11 can significantly increase the risk of non-small-cell lung cancer [NSCLC; odds ratio (OR)=3.41, 95% confidence interval (CI)=1.07-10.80; P=0.037] while reducing the overall survival (OS) time of patients with NSCLC [hazards ratio (HR)=2.83, 95% CI=1.97-4.07; P<0.001]. In addition, increased expression of SHP2/PTPN11 can significantly increase the risk of gastric (OR=5.35, 95% CI=1.81-15.77; P=0.002) and cervical cancer (OR=12.04, 95% CI=3.45-42.01; P<0.001). However, no significant difference could be found in the expression level of SHP2/PTPN11 in liver cancer (OR=1.47, 95% CI=0.37-5.84; P=0.582) compared with that in the adjacent normal tissues. Taken together, SHP2/PTPN11 was found to be expressed highly in a number of tumors, which was in turn associated with tumorigenesis and patient prognosis. In particular, increased expression of SHP2/PTPN11 can increase the risk of NSCLC, gastric cancer and cervical cancer, whereas higher expression levels of SHP2/PTPN11 can reduce OS of NSCLC."

基金机构：　

基金资助正文：